基础医学与临床 ›› 2014, Vol. 34 ›› Issue (1): 117-120.
• 短篇综述 • 上一篇 下一篇
韩尚容1,樊境朴1,潘燕1,李学军2
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
基金资助:
Received:
Revised:
Online:
Published:
Contact:
摘要: EGFR-TKI用药一段时间后出现的耐药现象是目前临床治疗的难题。本综述列举了EGFR-TKI耐药机制并介绍了多HER通路抑制、EGFR与VEGFR双通路抑制、作用于T790M突变靶点、抑制C-MET、促进PTEN(抑制PI3K)的表达及下游信号途径以及多种新型药物的抗EGFR-TKI耐药作用。
关键词: EGFR-TKI, 耐药, 治疗策略
Abstract: Acquired resistance to EGFR-TKI after a period of time has become a puzzle in clinic treatment. This review introduced the mechanism of acquired resistance to EGFR-TKI and focused on the recent discovered treatments after TKI resistance, including pan-HER TKI, EGFR-VEGFR double inhibition,C-MET inhibitor, PTEN activator and new drugs targeting EGFR mutation.
Key words: epidermal growth factor receptor- tyrosine kinase inhibitors, drug resistance, therapeutic strategies
中图分类号:
R730.53
韩尚容 樊境朴 潘燕 李学军. EGFR-TKI耐药后的治疗策略研究进展[J]. 基础医学与临床, 2014, 34(1): 117-120.
0 / / 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2014/V34/I1/117